Cytokines as predictors for sustained response and as markers for immunomodulation in patients with chronic hepatitis C. (Q42505913)

1 November 2017

Cytokines as predictors for sustained response and as markers for immunomodulation in patients with chronic hepatitis C. (English)

1 reference

1 November 2017

1 reference

Neuman MG

1

1 reference

1 November 2017

Benhamou JP

2

1 reference

1 November 2017

Malkiewicz IM

3

1 reference

1 November 2017

Akremi R

4

1 reference

1 November 2017

Shear NH

5

1 reference

1 November 2017

Asselah T

6

1 reference

1 November 2017

Ibrahim A

7

1 reference

1 November 2017

Boyer N

8

1 reference

1 November 2017

Martinot-Peignoux M

9

1 reference

1 November 2017

Jacobson-Brown P

10

1 reference

1 November 2017

Katz GG

11

1 reference

1 November 2017

Le Breton V

12

1 reference

1 November 2017

Le Guludec G

13

1 reference

1 November 2017

Suneja A

14

1 reference

1 November 2017

Marcellin P

15

1 reference

1 November 2017

1 May 2001

1 reference

1 November 2017

Clinical Biochemistry

1 reference

1 November 2017

34

1 reference

1 November 2017

3

1 reference

1 November 2017

173-182

1 reference

Immunopathogenesis of hepatitis C virus infection

1 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9120%2801%2900212-0

Interleukin-10 promoter polymorphism predicts initial response of chronic hepatitis C to interferon alfa

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9120%2801%2900212-0

Decreased frequency of HCV core-specific peripheral blood mononuclear cells with type 1 cytokine secretion in chronic hepatitis C.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9120%2801%2900212-0

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9120%2801%2900212-0

Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: role of membrane oxidative damage

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9120%2801%2900212-0

Retreatment with interferon-alpha and ribavirin in primary interferon-alpha non-responders with chronic hepatitis C.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9120%2801%2900212-0

Interferon-ribavirin combination therapy for chronic hepatitis C.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9120%2801%2900212-0

Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. The Swedish Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9120%2801%2900212-0

Ribavirin enhances the efficacy but not the adverse effects of interferon in chronic hepatitis C. Meta-analysis of individual patient data from European centers.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9120%2801%2900212-0

A phase I/II study of recombinant human interleukin-12 in patients with chronic hepatitis C.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9120%2801%2900212-0

Pathogenesis, natural history, treatment, and prevention of hepatitis C.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9120%2801%2900212-0

Interferon-alpha plus ribavirin in chronic hepatitis C resistant to previous interferon-alpha course: results of a randomized multicenter trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9120%2801%2900212-0

Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9120%2801%2900212-0

Predictors of sustained response to alpha interferon therapy in chronic hepatitis C

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9120%2801%2900212-0

Role of cytokines in ethanol-induced cytotoxicity in vitro in Hep G2 cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9120%2801%2900212-0

Genotypes and titers of hepatitis C virus for predicting response to interferon in patients with chronic hepatitis C.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9120%2801%2900212-0

Pathogenesis, diagnosis and management of hepatitis C.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9120%2801%2900212-0

Increases in intrahepatic CD68 positive cells, MAC387 positive cells, and proinflammatory cytokines (particularly interleukin 18) in chronic hepatitis C infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9120%2801%2900212-0

Soluble tumor necrosis factor receptors in chronic hepatitis C: a correlation with histological fibrosis and activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9120%2801%2900212-0

Serum concentrations of sIL-2R, IL-6, TGF-beta1, neopterin, and zinc in chronic hepatitis C patients treated with interferon-alpha

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9120%2801%2900212-0

Hepatitis C virus-specific T-cell reactivity during interferon and ribavirin treatment in chronic hepatitis C.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9120%2801%2900212-0

mRNA cytokine profile in peripheral blood cells from chronic hepatitis C virus (HCV)-infected patients: effects of interferon-alpha (IFN-alpha) treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9120%2801%2900212-0

Cytokines in viral hepatitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9120%2801%2900212-0

10.1016/S0009-9120(01)00212-0

7 January 2021

Identifiers

DOI

1 reference

1 November 2017

1 reference